Oral drug shows promise in shrinking tumors for rare genetic cancer syndrome
NCT ID NCT03401788
First seen Apr 14, 2026 · Last updated Apr 14, 2026
Summary
This study is testing an oral drug called belzutifan for people with von Hippel-Lindau (VHL) disease who have kidney tumors. The goal is to see if continuous daily treatment can shrink these tumors and delay the need for surgery. The study will also monitor how the drug affects other tumors caused by VHL and track any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VHL - VON HIPPEL-LINDAU SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus University Hospital
Aarhus, Denmark
-
Cambridge University Hospital
Cambridge, United Kingdom
-
Hospital Georges Pompidou
Paris, France
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
Vanderbilt Medical Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.